Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNG2 | P59768 | 5/20 | 0.80 |
| ▸ | GNB1 | P62873 | 5/20 | 0.80 |
| ▸ | PHLPP2 | Q6ZVD8 | 2/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | P2RY4 | P51582 | 8/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | P2RY12 | Q9H244 | 7/20 | 0.63 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.63 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.63 |
| ▸ | ENTPD1 | P49961 | 2/20 | 0.63 |
| ▸ | HPGDS | O60760 | 1/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3363896 | 0.99 | GNG2 (0.82) | GNG2GNB1PHLPP2CYP1A2CYP2C9 | |
| SCHEMBL13021512 | 0.93 | GNG2 (0.92) | GNG2GNB1PHLPP2CYP1A2CYP2C9 | |
| SCHEMBL3029899 | 0.90 | GNG2 (0.97) | GNG2GNB1PHLPP2CYP1A2CYP2C9 | |
| SCHEMBL790823 | 0.90 | GNG2 (0.83) | GNG2GNB1PHLPP2CYP1A2CYP2C9 | |
| SCHEMBL790523 | 0.89 | GNG2 (0.79) | GNG2GNB1PHLPP2CYP1A2CYP2C9 | |
| SCHEMBL3021101 | 0.89 | GNG2 (0.82) | GNG2GNB1PHLPP2CYP1A2CYP2C9 | |
| SCHEMBL3026032 | 0.89 | GNG2 (0.82) | GNG2GNB1PHLPP2CYP1A2CYP2C9 | |
| SCHEMBL2778161 | 0.89 | GNG2 (1.00) | GNG2GNB1PHLPP2CYP1A2CYP2C9 | |
| SCHEMBL13213975 | 0.89 | GNG2 (0.86) | GNG2GNB1PHLPP2CYP1A2CYP2C9 | |
| SCHEMBL29354288 | 0.89 | GNG2 (1.00) | GNG2GNB1PHLPP2CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113727999-A | Methods and compositions for treating cancer | 奥默罗斯公司 | 2021-11-30 | — | — | CN | disclosed |
| EP-3908601-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | Omeros Corporation (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20200345725-A1 | Methods and Compositions for Treating Cancer | OMEROS CORPORATOIN | 2020-11-05 | — | — | US | disclosed |
| WO-2020146795-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2020-07-16 | — | — | WO | disclosed |
| EP-2129653-B1 | NOVEL P2Y12 RECEPTOR ANTAGONISTS | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2017-05-17 | — | — | EP | disclosed |
| US-20100210654-A1 | NOVEL P2Y12 RECEPTOR ANTAGONISTS | RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN (DE) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210654-A1 | NOVEL P2Y12 RECEPTOR ANTAGONISTS | P2RY12, P2RY11, P2RY13 | GNG2 233/4885GNB1 314/4885PHLPP2 415/4885 |
| US-20200345725-A1 | Methods and Compositions for Treating Cancer | LPAR5, LPAR3, LPAR1 | GNG2 41/4885GNB1 35/4885PHLPP2 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.